Burkitt lymphoma presenting as cecum mass and spontaneous tumor lysis syndrome with hypercalcemia.

Burkitt's lymphoma (BL) could be primarily presented with various symptoms. We reported a woman with abdominal pain and mass who later developed spontaneous TLS with hypercalcemia, and was diagnosed with BL. Clinicians should suspect BL in case of any abdominal mass, especially with an aggressive course, to avoid further complications.

Delayed-onset heparin-induced thrombocytopenia complicated with saddle embolus.

Delayed-onset heparin-induced thrombocytopenia is a rare complication of heparin in which thrombocytopenia and thrombosis occur several days after heparin cessation. We describe a 47-year-old female patient with a history of melanoma and multiple surgeries presented to the emergency department with acute dyspnea and chest pain on the eighth day after discharge.

Large papillary thyroid cancer bed recurrence causing overlying skin ulceration and bleeding.

Salvage surgery is an acceptable option for palliative treatment of thyroid bed recurrence in metastatic papillary thyroid carcinoma when other non-invasive options fail to control local skin complications.

Spontaneous tumor lysis syndrome in adrenal adenocarcinoma: a case report and review of the literature.

Background: Tumor lysis syndrome is an oncologic emergency that classically occurs following cancer therapy, although spontaneous tumor lysis syndrome can also occur in malignancies, albeit rarely. Spontaneous tumor lysis syndrome has previously been reported in some hematologic malignancies, but it rarely happens in solid tumors and seems to be associated with a higher mortality rate. This is the first case of adrenal adenocarcinoma that developed spontaneous tumor lysis syndrome.

Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.

In this study, efficacy and safety of interferon (IFN) β-1b in the treatment of patients with severe COVID-19 were evaluated. Among an open-label, randomized clinical trial, adult patients (≥18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group. Patients in the IFN group received IFN β-1b (250 mcg subcutaneously every other day for two consecutive weeks) along with the national protocol medications while in the control group, patients received only the national protocol medications (lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7-10 days).